Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced dosing the first patient in a Phase 1 trial of NL-201 for advanced solid tumors. NL-201 is a de novo protein designed to mimic the therapeutic activity of natural cytokines IL-2 and IL-15. The Phase 1 study will be conducted at multiple sites in Australia and North America. The…
Researchers looking to help people suffering from addiction, depression, and pain are studying how certain brain neurons operate to see if they can be controlled. In a paper published May 11 in Neuron, researchers at the University of Washington School of Medicine and Washington University in St. Louis, along with several other universities, successfully used a protein called parapinopsin to turn off…
Researchers at the Allen Institute are on a quest to understand everything they can about the microscopic defense system coursing through our blood — our immune cells. The human immune system touches all aspects of health and disease, as the last year’s global pandemic has all too painfully highlighted. But many characteristics of the system remain poorly understood, especially when…
The Infectious Disease Research Institute (IDRI), Duke Human Vaccine Institute, and 3M have collaborated to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV2, as well as other coronaviruses. Study results published in the May 10th edition of Nature show the vaccine candidate, which combines a nanoparticle developed by a Duke-led research team with IDRI’s…
Early in the pandemic, it was thought that the SARS-CoV-2 virus attacked blood vessels and the heart with just as much vigor as it did the lungs. But now, just over a year later, a new study shows that the virus attacks the lungs and the lining of lung tissue, and that injury to blood vessels may be less common. In research published…
Seattle Children’s today announced that Anu and Satya Nadella and their family have generously committed $15 million to advance precision medicine neurosciences and youth mental health care at Seattle Children’s, and to help provide equitable access to care for every family and community. Seattle Children’s today announced that Anu and Satya Nadella and their family have generously committed $15 million…
The Institute for Stem Cell and Regenerative Medicine (ISCRM) is pleased to welcome a new faculty member, Thelma Escobar, who this month joins the Department of Biochemistry as an Assistant Professor. Escobar’s lab will combine stem cell biology, immune biology, and biochemistry to investigate how histone inheritance preserves chromatin domains, to identify mechanisms for cell fate determination, and to answer…
New funding: Gene-sequencing startup TwinStrand Biosciences raised $50 million in a Series B round led by Section 32, a California-based fund focused on biotech, technology, healthcare and life sciences. Total venture capital funding is now north of $70 million for the 6-year-old company. Double strands of innovation: TwinStrand, which spun out of the University of Washington, has developed technology in…
A tiny swimming, crawling worm may not seem like an animal that can tell us much about humans. But appearances can be deceiving. “We actually face quite a lot of similar challenges as other animals on this earth do. They have to figure out how to survive, how to reproduce, how to find their food. Those things are fundamental,” said…
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced dosing the first patient in a Phase 1 trial of NL-201 for advanced solid tumors. NL-201 is a de novo protein designed to mimic the therapeutic activity of natural cytokines IL-2 and IL-15. The Phase 1 study will be conducted at multiple sites in Australia and North America. The…